XML 93 R79.htm IDEA: XBRL DOCUMENT v3.23.2

Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details) € in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 717	€ 779
Bayer contingent consideration arising from acquisition of Genzyme
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Payment to sale of business period	10 years
Fair value of contingent consideration payable		€ 13	26
Increase in fair value of liability		1.00%
Bayer contingent consideration arising from acquisition of Genzyme | Top of range
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Potentiel payments related to percentage of sales of alemtuzumab | $	$ 1,250
MSD contingent consideration (European Vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 133	204
Increase in fair value of liability		1.00%
Shire contingent consideration arising from acquisition of Translate Bio
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 389	380
Increase in fair value of liability		13.00%
Contingent consideration arising from acquisition of Amunix
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 178	€ 165
Increase in fair value of liability		1.00%

X

- Definition

The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2022-03-24
-Paragraph B67
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Payment to sale of business period.

+ References

No definition available.

+ Details

Name:	sny_PaymentToSaleOfBusinessPeriod
Namespace Prefix:	sny_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage increase in fair value liabilities.

+ References

No definition available.

+ Details

Name:	sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix:	sny_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Potential payments related to percentage of sales.

+ References

No definition available.

+ Details

Name:	sny_PotentialPaymentsRelatedToPercentageOfSales
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: